2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.058 Qingqing Xu NACLC23 Abstract

PP01.058 Qingqing Xu NACLC23 Abstract

Pdf Summary

A study was conducted to assess the real-world outcomes of patients with non-small cell lung cancer (NSCLC) who received second- (2L) or third-line (3L) treatment with docetaxel. The study included data from three databases and analyzed the treatment patterns and outcomes of patients diagnosed with NSCLC between 2017 and 2022 who received docetaxel after first-line platinum-based chemotherapy with or without immunotherapy. <br /><br />The study included data from 627 patients, with 505 (81%) in the 2L and 122 (19%) in the 3L. The median age at 2L/3L initiation was 67 years, and 55% of the patients were male. Most patients (86%) had stage 3B or 4 NSCLC at diagnosis, and 50% had an ECOG performance status of 0-1 at 2L/3L initiation.<br /><br />The treatment patterns varied, with different combinations of chemotherapy, immunotherapy, and targeted therapies being used in the different treatment lines. The time-to-event outcomes, which included overall survival (OS), progression-free survival (PFS), time to treatment discontinuation (TTD), and time to next treatment or death (TTNTD), were presented in a table.<br /><br />The analysis revealed that there is a high unmet need for novel treatments for patients with epidermal growth factor receptor (EGFR) wildtype non-squamous NSCLC in the second- and third-line settings. The study emphasizes the importance of developing targeted therapies to improve outcomes for these patients.

Keywords

non-small cell lung cancer

NSCLC

second-line treatment

third-line treatment

docetaxel

platinum-based chemotherapy

immunotherapy

treatment patterns

overall survival

targeted therapies